Marshall Wace’s Biolase, Inc. BIOL Stock Holding History

Marshall Wace’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-29	Closed	-$27K	–	4194
2021 Q4	$27K	Sell	29 -272	-90%	-$343K	﹤0.01%	3669
2021 Q3	$481K	Buy	+301	New	+$491K	﹤0.01%	2408

Other funds holding BIOL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Zhang Financial Portage, Michigan $2.89B AUM 18.44% 1-Year Est. Return

Marshall Wace's BIOL Position: Q1 2022 in Review

Marshall Wace sold out of Biolase, Inc. (BIOL) in Q1 2022, closing a stake of 29 shares — an estimated $27K sold.

Marshall Wace first reported a position in BIOL in Q3 2021 and held it in 2 quarters. The position peaked at $481K in Q3 2021. 28 funds tracked by Wall St. Rank hold BIOL as of Q1 2022.

Marshall Wace reported no remaining Biolase, Inc. position as of Q1 2022 after selling out during the quarter.
Marshall Wace sold 29 Biolase, Inc. shares in Q1 2022, an estimated $27K.
Marshall Wace first reported a position in Biolase, Inc. in Q3 2021 and held it in 2 quarters.
Marshall Wace's Biolase, Inc. position peaked at $481K in Q3 2021.
28 funds tracked by Wall St. Rank held Biolase, Inc. as of Q1 2022.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.